Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of “Hold” by Brokerages

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been assigned an average recommendation of “Hold” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $31.8333.

Several equities research analysts recently weighed in on STRO shares. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sutro Biopharma in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Monday, December 22nd. Wedbush reaffirmed a “neutral” rating and set a $100.00 price target (up from $20.00) on shares of Sutro Biopharma in a report on Tuesday, December 2nd. HC Wainwright increased their price target on shares of Sutro Biopharma to $10.00 and gave the stock a “neutral” rating in a research report on Monday, December 22nd. Finally, Citigroup upgraded shares of Sutro Biopharma to an “outperform” rating in a research report on Tuesday, January 20th.

Sutro Biopharma Stock Performance

NASDAQ:STRO opened at $22.93 on Wednesday. Sutro Biopharma has a fifty-two week low of $5.23 and a fifty-two week high of $26.54. The company has a market cap of $195.23 million, a price-to-earnings ratio of -0.88 and a beta of 1.47. The stock has a fifty day moving average price of $17.37 and a 200-day moving average price of $12.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Invesco Ltd. boosted its stake in shares of Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares in the last quarter. AQR Capital Management LLC lifted its stake in Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company’s stock valued at $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Strs Ohio bought a new position in Sutro Biopharma in the 1st quarter valued at approximately $99,000. Savant Capital LLC acquired a new stake in Sutro Biopharma in the second quarter valued at approximately $37,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in Sutro Biopharma in the second quarter valued at approximately $27,000. Institutional investors own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.